美股A股
StockGist

Schrödinger, Inc.

SDGRNASDAQ · Healthcare · Medical - Healthcare Information Services
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and m…
$29.53-4.28%
报价 2026-11-13
市值
$1.95B
EV
$1.94B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -11.6%
$11.07$33.39

筛选结果

pipeline · 2026-11-13
Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool

爆发潜力

2026-11-13
未命中✗ 收入线✗ EPS 线
财年收入倍数EPSPE
FY+22027-120.9x-0.79 → -1.42—
FY+32028-121.0x-0.79 → -0.97—

毛利率 59% · TTM 收入 $269M · 基数 EPS -0.79(调整后)

电话会信号

辅助标签
Q3 20262026-11-04
AI 词频高上调指引
指引 上调
信心 4
分析师 4

“We now expect full year 2026 ACV of $222 million to $232 million, representing 12% to 17% growth over 2025.”

原文引用(1)
  • 上调指引:On the strength of this performance, we are raising our full year guidance for both ACV and drug discovery revenue.

蓝色标签在暴涨研究中略有区分度;悬停查看口径。

研究结论

还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。

去生成基本面报告 →

历史股价

加载中…

事件

0 条 · 随区间与图例筛选

该区间内无事件。

同行对比

FMP 同行列表 · 2026-05-16
公司市值今日预期营收增速毛利率PEEV/EBITDAP/FCF池
SDGRSchrödinger, Inc.$1.95B-4.3%+0.8%59.3%–––
TXG10x Genomics, Inc.$7.07B-1.5%-1.1%74.5%–204.2x66.8x
ABCLAbCellera Biologics Inc.$3.75B-1.1%–75%–––
PGNYProgyny, Inc.$2.66B-1.1%+7.7%24.5%31.7x18.5x12.3x
IMNMImmunome, Inc.$2.22B+0.4%-97.4%-1,161.9%–––
AZTAAzenta, Inc.$2B+4.1%+6.0%46%––70.1x
OMCLOmnicell, Inc.$1.61B+0.2%+3.8%44.8%36.5x10.1x11.3x
TDOCTeladoc Health, Inc.$1.6B+1.3%-4.0%68.6%–7.6x7.0x
OMDAOmada Health$889M-2.5%+35.4%75.9%169.6x40.3x32.8x高增长
同行中位数––+3.8%57.3%36.5x18.5x22.5x

研究全文

L2 基本面 memo

尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。

财务报表

Metric
2026-09-30
Q3 2026
2026-06-30
Q2 2026
2026-03-31
Q1 2026
2025-12-31
Q4 2025
2025-09-30
Q3 2025
2025-06-30
Q2 2025
2025-03-31
Q1 2025
2024-12-31
Q4 2024
Revenue$64.5M$58.9M$58.6M$87.2M$54.3M$54.8M$59.6M$88.3M
Gross Margin59.3%55.1%50.4%65.7%51.6%47.8%52.3%72.6%
Operating Margin-40.5%-70.6%-83.3%-19.7%-84.6%-96.6%-85.5%-23.5%
Net Income$-37.7M$6M$-60M$32.5M$-32.8M$-43.2M$-59.8M$-40.2M
Diluted EPS-0.50.08-0.810.44-0.45-0.59-0.82-0.55
Operating Cash Flow$-47.6M$63.7M$-14.8M$-16.1M$-61.9M$-52.2M$144.1M$-31.1M

研究材料